CDG Invest Growth exits Soludia Maghreb
CDG sold its stake to Sothema, a Moroccan pharmaceutical company.
** For the best experience, download the free Africa Private Equity News app Android | iOS **
CDG Invest Growth’s Capmezzanine III fund has exited Morocco-based Soludia Maghreb, a key player in the manufacturing of hemodialysis products – used to filter waste and excess fluid from the blood when kidneys fail. CDG sold its stake to Sothema, a Moroccan pharmaceutical company.
Founded in 1998, Soludia Maghreb specialises in the manufacturing of hemodialysis concentrates and the distribution of pharmaceutical products and medical devices sourced from international laboratories.
Since its December 2021 investment in Soludia Maghreb, CDG Invest Growth has actively backed the company’s expansion. Key initiatives have included modernising the industrial platform, diversifying into new therapeutic areas, bolstering the sales force, and driving growth through both geographic expansion and strategic acquisitions.
Hassan Laaziri, CEO of CDG Invest Growth, stated: “This transaction reflects the successful partnership between CDG Invest Growth and Soludia Maghreb, built on the strengthening of the company’s operational fundamentals and the acceleration of its growth trajectory. The handover to a leading industrial player such as Sothema represents a major milestone and opens up enhanced industrial and commercial development prospects for Soludia Maghreb.”
Want to know who is raising, investing, and exiting in Africa? Get Africa Private Equity News’ monthly Dealmaker’s Log – a database of reported investment deals, exits, and fundraising closes. Subscribe now